Faron Pharmaceuticals H1: Advancing to registrational trials
27 augusti, 16:50
27 augusti, 16:50
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report. While the report did not include any major surprises, the company managed to maintain a relatively low OPEX despite concluding its BEXMAB study. Backed by encouraging clinical data and positive feedback from the FDA, we believe that the company is well-positioned for the upcoming pivotal study and a potential license deal.
27 augusti, 16:50
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report. While the report did not include any major surprises, the company managed to maintain a relatively low OPEX despite concluding its BEXMAB study. Backed by encouraging clinical data and positive feedback from the FDA, we believe that the company is well-positioned for the upcoming pivotal study and a potential license deal.
Krypto
Krypto
1 DAG %
Senast
Castellum
Igår, 17:32
Här är de 15 mest blankade aktierna
OMX Stockholm 30
1 DAG %
Senast
2 625,70